Skip to main content
SpringerLink
Log in

Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

Lupus low disease activity state (LLDAS) is a treatment target for patients with SLE and is associated with decreased risk for severe flare and new damage. We investigated the utility of the achievement of LLDAS in children with lupus nephritis and whether attainment of LLDAS is associated with more favorable outcomes.

Methods

Data of children, diagnosed with biopsy-proven lupus nephritis between January 2012 and December 2020, were retrospectively analyzed.

Results

For patients who did not achieve LLDAS after initial treatment (first 6 months), presence of autoimmune hemolytic anemia (62% vs. 18%, p = 0.047), anti-Sm (85% vs. 18%, p = 0.003) and anti-dsDNA (77% vs. 27%, p = 0.038) antibodies, proliferative lupus nephritis (77% vs. 27%, p = 0.038), and hypertension (69% vs. 9%, p = 0.005) at onset were more frequently encountered. Also, a lower rate of complete kidney response (43% vs. 100%, p = 0.005) and a higher rate of hypertension (86% vs. 13%, p = 0.002) were observed in patients who did not achieve LLDAS-50, defined as being in LLDAS at least 50% of the observation time. Attainment of both LLDAS after initial treatment and LLDAS-50 were associated with lower rates of kidney flare (p = 0.001 and p = 0.002, respectively) and damage accrual (p = 0.007 and p = 0.02, respectively) through the observation period.

Conclusions

LLDAS is an attainable treatment target for children with lupus nephritis and associated with lower rates of kidney flare and damage. Presence of hematologic involvement, hypertension, and proliferative lupus nephritis at onset adversely influenced the early achievement of LLDAS.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kamphuis S, Silverman ED (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6:538–546

    Article  CAS  PubMed  Google Scholar 

  2. Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 36:1377–1385

    Article  PubMed  Google Scholar 

  3. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713–723

    Article  CAS  PubMed  Google Scholar 

  4. Groot N, de Graeff N, Marks SD, Brogan P et al (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76:1965–1973

    Article  CAS  PubMed  Google Scholar 

  5. Golder V, Tsang-A-Sjoe MWP (2020) Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford) 59:v19–v28

    Article  CAS  PubMed  Google Scholar 

  6. Franklyn K, Lau CS, Navarra SV, Louthrenoo W et al (2016) Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75:1615–1621

    Article  CAS  PubMed  Google Scholar 

  7. Tselios K, Gladman DD, Urowitz MB (2019) How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum 48:1035–1040

    Article  PubMed  Google Scholar 

  8. Wahadat MJ, van den Berg L, Timmermans D, van Rijswijk K et al (2021) LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med 8:e000571

    Article  PubMed  PubMed Central  Google Scholar 

  9. Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K et al (2022) Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in Childhood Lupus. Rheumatology (Oxford) 61:3378–3389

    Article  PubMed  Google Scholar 

  10. Piga M, Floris A, Cappellazzo G, Chessa E et al (2017) Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 19:247

    Article  PubMed  PubMed Central  Google Scholar 

  11. Petri M, Orbai AM, Alarcón GS, Gordon C et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686

    Article  PubMed  PubMed Central  Google Scholar 

  12. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250

    Article  PubMed  Google Scholar 

  13. Yu F, Haas M, Glassock R, Zhao MH (2017) Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13:483–495

    Article  PubMed  Google Scholar 

  14. Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904

    Article  PubMed  Google Scholar 

  15. Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291

    PubMed  Google Scholar 

  16. Golder V, Kandane-Rathnayake R, Huq M, Nim H et al (2019) Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol 1:e95–e102

    Article  Google Scholar 

  17. Ruperto N, Hanrahan LM, Alarcón GS, Belmont HM et al (2011) International consensus for a definition of disease flare in lupus. Lupus 20:453–462

    Article  CAS  PubMed  Google Scholar 

  18. Gladman D, Ginzler E, Goldsmith C, Fortin P et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  CAS  PubMed  Google Scholar 

  19. Hao Y, Oon S, Ji L, Gao D et al (2022) Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clin Rheumatol 41:357–366

    Article  PubMed  Google Scholar 

  20. Kikuchi J, Hanaoka H, Saito S, Oshige T et al (2022) Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keac002

  21. Ozturk K, Caglayan S, Tanatar A, Baglan E et al (2021) Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus 30:2144–2150

    Article  CAS  PubMed  Google Scholar 

  22. Qiu S, Zhang H, Yu S, Yang Q et al (2022) Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol 37:367–376

    Article  PubMed  Google Scholar 

  23. Babaoglu H, Li J, Goldman D, Magder LS, Petri M (2019) Predictors of predominant lupus low disease activity state (LLDAS-50). Lupus 28:1648–1655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gao D, Hao Y, Mu L, Xie W et al (2020) Frequencies and predictors of the lupus low disease activity state and remission in treatment-naïve patients with systemic lupus erythematosus. Rheumatology (Oxford) 59:3400–3407

    Article  CAS  PubMed  Google Scholar 

  25. De Mutiis C, Wenderfer SE, Orjuela A, Bagga A et al (2022) Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology (Oxford) 61:2563–2571

    Article  PubMed  Google Scholar 

  26. Mina R, Abulaban K, Klein-Gitelman MS, Eberhard BA et al (2016) Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res 68:195–202

    Article  Google Scholar 

  27. Suhlrie A, Hennies I, Gellermann J, Büscher A et al (2020) Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 35:1235–1246

    Article  PubMed  Google Scholar 

  28. Ruggiero B, Vivarelli M, Gianviti A, Benetti E et al (2013) Lupus nephritis in children and adolescents: results of the Italian collaborative study. Nephrol Dial Transplant 28:1487–1496

    Article  CAS  PubMed  Google Scholar 

  29. Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B et al (2021) Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med 8:e000590

    Article  PubMed  PubMed Central  Google Scholar 

  30. Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685–708

    Article  PubMed  Google Scholar 

  31. Perazella MA, O’Leary MP (2022) Etiology and evaluation of hematuria in adults. https://www.uptodate.com/contents/etiology-and-evaluation-of-hematuria-in-adults. Accessed 15 July 2022

  32. Touma Z, Urowitz MB, Ibañez D, Gladman DD (2011) SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 20:67–70

    Article  CAS  PubMed  Google Scholar 

  33. Houssiau FA, Vasconcelos C, D’Cruz D, de Ramon GE et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940

    Article  PubMed  Google Scholar 

  34. Dall’Era M, Cisternas MG, Smilek DE, Houssiau FA et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67:1305–1313

    Article  CAS  PubMed  Google Scholar 

  35. Wu JY, Yeh KW, Huang JL (2014) Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 43:513–520

    Article  PubMed  Google Scholar 

  36. Conti F, Ceccarelli F, Perricone C, Leccese I et al (2017) The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 25:719–726

    Article  Google Scholar 

  37. Holland MJ, Beresford MW, Feldman BM, Huggins J et al (2018) Measuring disease damage and its severity in childhood-onset systemic lupus erythematosus. Arthritis Care Res 70:1621–1629

    Article  Google Scholar 

  38. Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, De Uña-Álvarez J et al (2019) Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Semin Arthritis Rheum 48:1025–1029

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Rheumatology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

    Hakan Kisaoglu, Ozge Baba & Mukaddes Kalyoncu

  2. Division of Pediatric Nephrology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

    Mukaddes Kalyoncu

Authors
  1. Hakan Kisaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozge Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mukaddes Kalyoncu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Kisaoglu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Graphical Abstract (PPTX 44 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kisaoglu, H., Baba, O. & Kalyoncu, M. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol 38, 1167–1175 (2023). https://doi.org/10.1007/s00467-022-05742-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-022-05742-8

Keywords

Search

Navigation